Skip to content

Outcomes Following Combined Adductoplasty™ and Lapiplasty® (MTA3D)

Radiographic and Patient Reported Outcomes Following Combined Adductoplasty™ and Lapiplasty® Procedures for Correction of Metatarsus Adductus and Hallux Valgus (MTA3D)

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05587569
Acronym
MTA3D
Enrollment
80
Registered
2022-10-20
Start date
2022-09-28
Completion date
2030-12-31
Last updated
2025-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hallux Valgus, Metatarsus Adductus

Keywords

Metatarsus Adductus, Hallux Valgus, MTA3D

Brief summary

Prospective, multicenter, unblinded study to evaluate outcomes of the Adductoplasty™ Procedure in combination with the Lapiplasty® Procedure for patients in need of metatarsus adductus and hallux valgus correction. Up to 80 subjects will be treated in this study at up to 13 clinical sites. Patients 14 years of age or older with symptomatic metatarsus adductus and hallux valgus will be eligible to participate based on the inclusion and exclusion criteria defined in the study protocol.

Detailed description

The objectives of this study are to evaluate outcomes of the Adductoplasty™ Procedure combined with the Lapiplasty® Procedure for patients in need of hallux valgus and metatarsus adductus surgery: 1. To evaluate the quality of life and pain scores following the Adductoplasty™ Procedure in combination with the Lapiplasty® Procedure. 2. To determine whether the Adductoplasty™ Procedure in combination with the Lapiplasty® Procedure, effectively corrects and maintains triplane anatomical alignment of the 1st, 2nd and 3rd metatarsals, the hallux position, the sesamoid position, and the foot width.

Interventions

DEVICETreatment of metatarsus adductus and hallux valgus with the Adductoplasty™ Procedure in combination with the Lapiplasty® Procedure

Patients 14 years of age or older with symptomatic metatarsus adductus and hallux valgus will be eligible to participate based on the inclusion/exclusion criteria established in the study protocol. Anticipated study duration will be 5 years post index procedure.

Sponsors

Treace Medical Concepts, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
14 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

1. Male and females ≥14 years old at the time of consent 2. Closed physeal plates at the time of consent 3. Intermetatarsal angle is ≥8.0˚; OR True IMA of \>10°, (IMA+MTA-15=True IMA) 4. Hallux valgus angle is ≥12.0˚ 5. Metatarsus adductus angle based on Sgarlatos method ≥15° 6. Willing and able to adhere to post-op care instructions 7. Capable of completing self-administered questionnaires 8. Acceptable surgical candidate, including use of general anesthesia 9. Female patients must be of non-childbearing potential or have a negative pregnancy test in accordance with hospital standards prior to the Index Procedure 10. Willing and able to schedule index procedure within 3 months of consent and able to return for scheduled follow-up visits 11. Willing and able to provide written informed consent 12. Patient agrees to refrain from any reconstructive procedures on contralateral foot for minimum of 6 months post index procedure

Exclusion criteria

1. Previous surgery for hallux valgus on operative side 2. Previous surgeries on operative foot involving fusion of foot or ankle joints (other than hammertoe, lesser toes/digits, or posterior muscle lengthening) 3. Moderate-severe osteoarthritis of the foot or ankle outside of the 1st, 2nd or 3rd tarsometatarsal joints 4. Severe osteoarthritis of the 1st, 2nd or 3rd tarsometatarsal joints 5. Any deformity of the hindfoot or midfoot that represents a pathological condition that may affect the outcome of the tarsometatarsal realignment, or a condition that requires concomitant surgical correction 6. BMI \>40 kg/m² 7. Current nicotine user in any form including vaping, smoking, oral ingestion or use of nicotine patch 8. Current clinical diagnosis of diabetes or currently taking medication for treatment of diabetes 9. Current clinical diagnosis of peripheral neuropathy 10. Current clinical diagnosis of fibromyalgia 11. Current clinical diagnosis of Complex Regional Pain Syndrome/Reflex Sympathetic Dystrophy (CRPS/RSD) 12. Current uncontrolled hypothyroidism 13. Current clinical diagnosis of chronic dependent edema 14. Previously sensitized to titanium 15. Currently taking oral steroids or rheumatoid biologics 16. Currently taking immunosuppressant drugs 17. Insufficient quantity or quality of bone to permit stabilization, conditions that inhibit healing (not including pathological fractures) and conditions causing poor blood supply such as peripheral vascular disease 18. Active, suspected, or latent infection in the affected area 19. Use of synthetic or allogenic bone graft substitutes 20. Use of non-Treace products for Index Procedure 21. Additional bone procedure needed during the index procedure to complete correction \[first MTP fusion, calcaneal osteotomy, traditional medial eminence resection, additional metatarsal or tarsal bone osteotomy or fusion (other than Weil osteotomies)\]; 22. Scheduled to undergo a same-day bilateral procedure 23. Patient has previously been enrolled into this study for a contralateral procedure 24. Scheduled for any concomitant procedure that would alter patient's ability to weight-bear post-procedure 25. Patient is actively involved with a workman's compensation case or is currently involved in litigation 26. Patient is currently in, or has participated in, a clinical study in the last 30 days prior to signing informed consent or is considering participation in another research protocol during this study. Exceptions to this include survey clinical studies with no treatment or if subject is greater than 12 months post procedure in either the Treace ALIGN3D™ or Mini3D™ Study without ongoing protocol defined AE 27. Patient has a condition or finding that, in the opinion of the Investigator, may jeopardize the patient's well-being, the soundness of this clinical study, or could interfere with provision of informed consent, completion of tests, therapy, or follow-up

Design outcomes

Primary

MeasureTime frameDescription
Radiographic recurrence of hallux valgus deformity with metatarsus adductus will be evaluated at 24 months for subjects wtih successful correction24 MonthsSuccessful correction is defined as two of the following three criteria: measured IMA \<9.0°, HVA \<15.0°, and TSP as ≤3 at 6 months post Adductoplasty® Procedure and Lapiplasty® Procedure. Recurrence at 24 months is defined by HVA \>15.0°.

Secondary

MeasureTime frameDescription
Radiographic Recurrence24 MonthsRadiographic recurrence of hallux valgus deformity at 24 months defined by HVA \>20°.
Clinical Complications60 MonthsClinical complications due to system implants the post-op instructions or health conditions that could affect other outcome measures.
Weight-Bearing Recovery Time12 MonthsAssessment of weight-bearing recovery time following the procedures. Weight-bearing will be measured in days and recorded based upon individual surgeon recovery protocol.
Time to Weight-Bear in Boot6 WeeksTime to start of weight-bearing in boot, in days.
Time to Weight-Bear in Shoes8 WeeksTime to start of weight-bearing in shoes, in days.
Union vs non-Union12 MonthsEvaluate clinical/radiographic healing (union vs non-union). Non-union is defined as pain and lucency at the 1st, 2nd, and/or 3rd TMT joint at 12 months post- Adductoplasty® Procedure and Lapiplasty® Procedure.
Change in Pain0-3 weeks, 6 weeks, 4 months, 6 months, 12 months, 24 months, 36 months, 48 months and 60 months post- Adductoplasty™ Procedure in combination with the Lapiplasty® Procedure, in comparison to baseline visit pain.Change in pain at the base of the big toe (bunion related), as well as the midfoot region for the operative foot only, assessed via the Visual Analog Scale (VAS) with 0-10 minimum and maximum values - with 0 being a better outcome and 10 being a worse outcome.
Change in Quality of Life6 months, 12 months, 24 months, 36 months, 48 months and 60 months post-Adductoplasty™ Procedure and Lapiplasty® Procedure, in comparison to baseline visitChange in Quality of Life, (PROMIS-29/PROMIS-25 and MOxFQ) defined as the total domain score measured.
Change in Range of Motion12 months, 24 months, 36 months, 48 months and 60 months post- Adductoplasty™ Procedure and Lapiplasty® Procedure, in comparison to baseline visitChange in Range of Motion - 1st MTP dorsiflexion and plantarflexion
Change in Osseous Foot Width12 months and 24 months post - Adductoplasty™ Procedure and Lapiplasty® Procedure, in comparison to baseline visitChange in osseous foot width - radiographically
Time to Return to Unrestricted Activity6 weeks - 6 months, post Lapiplasty® ProcedureTime to return to full unrestricted activity, in days.

Countries

United States

Contacts

Primary ContactCara Bethell
cbethell@treace.net(904) 373-5940
Backup ContactShana Zink
szink@treace.net(513) 265-0621

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026